Insight Molecular Diagnostics (IMDX) Other Non-Current Assets (2016 - 2026)

Insight Molecular Diagnostics has disclosed Other Non-Current Assets across 11 years of filings, most recently posting $1.2 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $1.2 million, down 29.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 29.41% YoY), and the FY2025 annual result was $593000.0, down 14.18% from the prior year.
• Other Non-Current Assets came in at $1.2 million for Q1 2026 at Insight Molecular Diagnostics, up from $593000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $2.1 million in Q4 2022 to a low of $329000.0 in Q2 2023.
• The 5-year median for Other Non-Current Assets is $691000.0 (2024), against an average of $995529.4.
• Across the five-year window, Other Non-Current Assets slumped 92.85% in 2022 and soared 364.48% in 2023, its largest moves.
• Insight Molecular Diagnostics' Other Non-Current Assets stood at $2.1 million in 2022, then declined by 19.85% to $1.7 million in 2023, then plunged by 59.35% to $691000.0 in 2024, then retreated by 14.18% to $593000.0 in 2025, then soared by 102.36% to $1.2 million in 2026.
• The last three Other Non-Current Assets figures came in at $1.2 million (Q1 2026), $593000.0 (Q4 2025), and $672000.0 (Q3 2025), per Business Quant data.